Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This short‐term study assessed changes in serum insulin‐like growth factor 1 (IGF‐1) over a 16‐week treatment period in a participant population diagnosed with acromegaly being treated with long‐acting somatostatin receptor ligands (SRL).
Epistemonikos ID: e63c32e5ec7d71e31b28d3d2c5afcd27476b5581
First added on: May 21, 2024